Elsevier research will be featured at upcoming Safety Pharmacology Society meeting
The 2019 Safety Pharmacology Society meeting will be in Barcelona from September 23-26, and the event is bringing together industry professionals to share best practices, enjoy networking opportunities, hear keynote speeches from thought leaders, and learn about hot research topics from experts in the field.
Elsevier’s own Dr. Matthew Clark, who serves as Director of Scientific Services for Elsevier R&D Solutions, will be participating in a comprehensive discussion on Thursday, September 26 titled Revisiting ICH S7A and S7B. “The aim of this session,” states the SPS program, “is to initiate discussions into guideline revisions in the future, to ensure continuation of their relevance for the current industry and protection of human volunteers and patients, by introducing additional flexibility for tailored-approaches.”
This relates to work that Elsevier has done in
collaboration with pharmaceutical industry scientists to elucidate the
scientific validity of animal-model-based drug tests. To understand the
relationship between animal and human toxicities, text mining and data
analytics were used on a PharmaPendium dataset that includes more than 3,000
drugs and 1.6 million adverse events.
The research led to Dr. Clark co-authoring this toxicity concordance study with Bayer last year, and just this summer he published a respiratory safety pharmacology translatability study with Novartis and Celerion in the Journal of Pharmacological and Toxicological Methods.
Both studies have had the impact of challenging the status quo, posing the question of whether standard respiratory animal studies are always warranted and what alternatives methods might be just as effective. As a result, regulators and industry are re-considering whether the standard animal studies should always be conducted. (Learn more about how Elsevier’s efforts could help curb animal testing in drug development here.)
The discussion at the upcoming SPS meeting will also offer
an opportunity for more people in the industry to learn about the findings from
the recent translatability study, which may inspire more pharma companies to
work with Elsevier to get data for similar issues beyond respiratory.